Literature DB >> 23089277

Uric acid stones and hyperuricosuria.

Tapan H Mehta1, David S Goldfarb.   

Abstract

Recent work has highlighted the strong relationships among obesity, diabetes, and the metabolic syndrome as causes of low urinary pH. Low urinary pH in turn is the major urinary risk factor for uric acid stones. Unlike calcium stones, uric acid stones can be dissolved and easily prevented with adequate urinary alkalinization. Recognizing the relevant risk factors should lead to increased identification of these radiolucent stones. The cornerstone of therapy is raising urinary pH; xanthine dehydrogenase inhibitors should be used only when urinary alkalinization cannot be achieved. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089277     DOI: 10.1053/j.ackd.2012.07.014

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  9 in total

1.  The visceral fat compartment is independently associated with changes in urine constituent excretion in a stone forming population.

Authors:  Ethan B Fram; Ilir Agalliu; Joseph DiVito; David M Hoenig; Joshua M Stern
Journal:  Urolithiasis       Date:  2015-04-23       Impact factor: 3.436

2.  Assessment of Urinary Inhibitor or Promoter Activity in Uric Acid Nephrolithiasis.

Authors:  Steeve Doizi; Kathy Rodgers; John Poindexter; Khashayar Sakhaee; Naim M Maalouf
Journal:  J Urol       Date:  2015-12-23       Impact factor: 7.450

Review 3.  Update on Uric Acid and the Kidney.

Authors:  Giana Kristy Ramos; David S Goldfarb
Journal:  Curr Rheumatol Rep       Date:  2022-04-14       Impact factor: 4.592

4.  Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis.

Authors:  Orestes Foresto-Neto; Bruno Ghirotto; Niels Olsen Saraiva Câmara
Journal:  Kidney360       Date:  2021-07-02

5.  Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones.

Authors:  Carmen Inés Rodriguez Cuellar; Peter Zhan Tao Wang; Michael Freundlich; Guido Filler
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

6.  Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.

Authors:  Haibo Yu; Xinying Liu; Yaxiang Song; Jiafen Cheng; Hui Bao; Ling Qin; Xuan Zhou; Ling Wang; Ai Peng
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

7.  Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.

Authors:  Daniel Hill-McManus; Elena Soto; Scott Marshall; Steven Lane; Dyfrig Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

Review 8.  Comorbidities in patients with crystal diseases and hyperuricemia.

Authors:  Sebastian E Sattui; Jasvinder A Singh; Angelo L Gaffo
Journal:  Rheum Dis Clin North Am       Date:  2014-02-19       Impact factor: 2.670

Review 9.  Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review.

Authors:  Guido Maarten Kamphuis; Jons Wouter van Hattum; Prim de Bie; Bhaskar K Somani
Journal:  Transl Androl Urol       Date:  2019-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.